Trials / Completed
CompletedNCT00873756
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
A Phase Ib Study of the Safety and Pharmacokinetics of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label study enrolling a total of up to 23 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FOLFOX regimen | Intravenous repeating dose |
| DRUG | bevacizumab | Intravenous repeating dose |
| DRUG | dulanermin | Intravenous repeating dose |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2014-03-01
- Completion
- 2014-04-01
- First posted
- 2009-04-02
- Last updated
- 2016-11-02
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00873756. Inclusion in this directory is not an endorsement.